Abstract
FOXP3 is essential for the development and function of regulatory CD4+CD25hi T (Treg) cells. However, recent evidence suggests that FOXP3 alone is not sufficient to completely explain the regulatory phenotype of these key players in autoimmunity and inflammation: after being activated, conventional human CD4+ T cells transiently up-regulate FOXP3 without acquiring a regulatory function. Researchers have recently found that glycoprotein A repetitions predominantly (GARP, or LRRC32) is a Treg-specific receptor that binds latent TGF-β and dominantly controls FOXP3 and the regulatory phenotype via a positive feedback loop. This finding provides a missing link in our molecular understanding of FOXP3 in Treg cells. This viewpoint focuses on GARP as safeguard of FOXP3 and the regulatory phenotype.
Keywords: Regulatory T cells, FOXP3, GARP, TGF-β, LAP, positive feedback
Current Molecular Medicine
Title: FOXP3: Required but Not Sufficient. The Role of GARP (LRRC32) as a Safeguard of the Regulatory Phenotype
Volume: 10 Issue: 6
Author(s): M. Probst-Kepper, R. Balling and J. Buer
Affiliation:
Keywords: Regulatory T cells, FOXP3, GARP, TGF-β, LAP, positive feedback
Abstract: FOXP3 is essential for the development and function of regulatory CD4+CD25hi T (Treg) cells. However, recent evidence suggests that FOXP3 alone is not sufficient to completely explain the regulatory phenotype of these key players in autoimmunity and inflammation: after being activated, conventional human CD4+ T cells transiently up-regulate FOXP3 without acquiring a regulatory function. Researchers have recently found that glycoprotein A repetitions predominantly (GARP, or LRRC32) is a Treg-specific receptor that binds latent TGF-β and dominantly controls FOXP3 and the regulatory phenotype via a positive feedback loop. This finding provides a missing link in our molecular understanding of FOXP3 in Treg cells. This viewpoint focuses on GARP as safeguard of FOXP3 and the regulatory phenotype.
Export Options
About this article
Cite this article as:
Probst-Kepper M., Balling R. and Buer J., FOXP3: Required but Not Sufficient. The Role of GARP (LRRC32) as a Safeguard of the Regulatory Phenotype, Current Molecular Medicine 2010; 10 (6) . https://dx.doi.org/10.2174/1566524011009060533
DOI https://dx.doi.org/10.2174/1566524011009060533 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Strategies for Skeletal Muscle Targeting in Drug Discovery
Current Pharmaceutical Design Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance
Current Medicinal Chemistry Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Metallothionein as a Negative Regulator of Pulmonary Inflammation
Current Pharmaceutical Biotechnology The Use of Molecular Docking and Spectroscopic Methods for Investigation of The Interaction Between Regorafenib with Human Serum Albumin (HSA) and Calf Thymus DNA (Ct-DNA) In The Presence Of Different Site Markers
Protein & Peptide Letters Damnacanthal: A Promising Compound as a Medicinal Anthraquinone
Anti-Cancer Agents in Medicinal Chemistry Xanthomicrol: A Comprehensive Review of Its Chemistry, Distribution, Biosynthesis and Pharmacological Activity
Mini-Reviews in Medicinal Chemistry Prospects for Developing New Antibacterials Targeting Bacterial Type IIA Topoisomerases
Current Topics in Medicinal Chemistry Actin and Keratin are Binding Partners of the 1,25D<sub>3</sub>-MARRS Receptor/PDIA3/ERp57
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Chemokine System as a Therapeutic Target in Autoimmune Thyroid Diseases: A Focus on the Interferon-γ Inducible Chemokines and their Receptor
Current Pharmaceutical Design Targeting Death Receptors to Fight Cancer: From Biological Rational to Clinical Implementation
Current Medicinal Chemistry Role of Regulatory T Cells in Allergy: Implications for Therapeutic Strategy
Inflammation & Allergy - Drug Targets (Discontinued) Neuroinflamm-Aging and Neurodegenerative Diseases: An Overview
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Therapies Targeting Oxidative Stress for Human Diseases: Where Are We Now?)
Current Pharmaceutical Biotechnology Poly(ADP-Ribosylation): Beneficial Effects of Its Inhibition
Current Enzyme Inhibition Chemokines: Central Mediators of the Innate Response to Sepsis
Current Immunology Reviews (Discontinued) Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) Targeting the Resistance of Pancreatic Cancer Cells to Nutrient Deprivation: Anti-Austerity Compounds
Current Drug Delivery Toll-Like Receptors and their Role in Hematologic Malignancies
Current Molecular Medicine